Chronic Spontaneous Urticaria (CSU): Symptoms & Omalizumab

Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), is a common and debilitating skin condition characterized by the sudden appearance of itchy wheals (hives) and/or angioedema for six weeks or longer without a known external trigger. It affects approximately 0.5–1% of the population worldwide, with a higher prevalence in adults, particularly women. The unpredictability of flare-ups and the intense itching can significantly impair quality of life, affecting sleep, work, and social activities. While the exact cause of CSU remains elusive in many cases, advances in understanding its pathophysiology have led to targeted treatments, notably omalizumab for chronic urticaria, which has revolutionized management for patients who do not respond to standard antihistamine therapy.

What Is Chronic Spontaneous Urticaria (CSU)?

Chronic spontaneous urticaria is defined by the recurrent appearance of hives (urticaria) without an identifiable external trigger. The term 'spontaneous' distinguishes it from inducible urticarias (e.g., physical urticaria due to pressure, cold, or heat). In CSU, the wheals appear spontaneously and can occur daily or almost daily for more than six weeks. Angioedema, a deeper swelling of the subcutaneous or submucosal tissues, often accompanies the hives in about 40–50% of patients. The condition can persist for months to years, with an average duration of 2–5 years, though some patients experience symptoms for longer periods.

The pathophysiology of CSU involves activation of cutaneous mast cells and basophils, leading to release of histamine and other inflammatory mediators such as leukotrienes, prostaglandins, and cytokines. This degranulation is driven by autoimmune mechanisms in a significant subset of patients, including type I autoantibodies (IgE against autoantigens) and type IIb autoantibodies (IgG against the high-affinity IgE receptor FcεRI or IgE itself). Other non-autoimmune factors, such as defects in the coagulation cascade, complement system, and neuropeptides, may also contribute. The heterogeneity of underlying mechanisms explains why response to treatments varies among individuals.

Symptoms of Chronic Spontaneous Urticaria

The hallmark symptoms of CSU include the appearance of wheals that are:

• Raised, red or skin-colored welts that vary in size and shape.
• Intensely itchy, often with a burning or stinging sensation.
• Transient, typically lasting less than 24 hours before fading without scarring.
• Recurrent, appearing at different sites on the body.

In addition to wheals, many patients experience angioedema, which presents as deeper swelling of the lips, eyelids, hands, feet, or genitalia. Angioedema can be painful rather than itchy and may last up to 72 hours. The unpredictable nature of these episodes often causes significant anxiety and distress. Some patients report triggers such as stress, heat, non-steroidal anti-inflammatory drugs (NSAIDs), or alcohol, but these are exacerbating factors rather than root causes.

Diagnosis of CSU

Diagnosis of chronic spontaneous urticaria is primarily clinical, based on a detailed history and physical examination. There are no specific diagnostic tests for CSU, but laboratory evaluations may help rule out underlying causes or associated conditions. The EAACI/GA²LEN/EDF/WAO guidelines recommend a stepwise approach:

• History: duration, frequency, size, and distribution of wheals; presence of angioedema; family history; possible triggers; previous treatments.
• Physical examination: active wheals, angioedema, dermatographism.
• Basic laboratory tests: complete blood count, erythrocyte sedimentation rate, C-reactive protein, and thyroid autoantibodies. Additional tests may include tryptase, complement levels, or skin biopsy if atypical features are present.

A thorough evaluation is essential to exclude other conditions such as urticarial vasculitis, autoimmune diseases, or infections. The diagnosis of chronic idiopathic urticaria is made when no underlying cause is identified, which is the case in most patients.

Impact on Quality of Life

Chronic spontaneous urticaria can severely impair quality of life. The intense itching and unpredictability of flare-ups disrupt sleep, concentration, and daily activities. Many patients report feeling embarrassed by visible wheals, leading to social withdrawal and emotional distress. Studies have shown that CSU patients have higher rates of anxiety and depression compared to the general population, and the condition's chronic nature often leads to significant healthcare utilization and economic burden. Effective management is therefore crucial not only for symptom control but for overall well-being.

Treatment Options for Chronic Spontaneous Urticaria

The treatment of CSU follows a stepwise approach based on international guidelines. The primary goal is to achieve complete symptom control while minimizing side effects. Initial management includes:

First-Line: Second-Generation Antihistamines

Second-generation antihistamines (e.g., loratadine, cetirizine, fexofenadine, levocetirizine, desloratadine) are the mainstay of therapy. They are taken daily and can be increased up to four times the standard dose if needed (updosing). They are well-tolerated with minimal sedation. Many patients achieve adequate control with antihistamines alone, but up to 50% may require additional options.

Second-Line: Add-On Therapies

For patients not responding to high-dose antihistamines, options include:

• Omalizumab for chronic urticaria: A monoclonal antibody targeting IgE, approved for CSU patients aged 12 years and older. Omalizumab reduces mast cell activation and significantly improves symptoms in about 65–70% of patients, often within 1–4 weeks. It is administered subcutaneously every 2–4 weeks.
• Leukotriene receptor antagonists (e.g., montelukast) may help in a subset of patients.
• Cyclosporine A, dapsone, or systemic corticosteroids for short-term control in severe, refractory cases, though long-term use of corticosteroids is discouraged due to side effects.

Third-Line: Other Immunomodulators

For patients who fail omalizumab or cannot access it, alternatives such as mycophenolate mofetil, methotrexate, or phototherapy may be considered, though evidence is limited. Newer therapies targeting IL-1, IL-4, IL-13, or other pathways are under investigation.

Omalizumab: Mechanism and Use in CSU

Omalizumab is a humanized monoclonal antibody that binds to free IgE, preventing its binding to the high-affinity receptor FcεRI on mast cells and basophils. This leads to downregulation of FcεRI on these cells and reduces their susceptibility to activation. In CSU, omalizumab also has immunomodulatory effects beyond IgE blockade, including reduced expression of inflammatory mediators. It is approved for omalizumab for chronic urticaria in patients who remain symptomatic despite H1-antihistamine treatment.

Clinical trials have demonstrated that omalizumab significantly reduces itch and hive count, with a good safety profile. The most common side effects include injection-site reactions, headache, and nausea. Rare but serious risks include anaphylaxis (0.1–0.2%) and potential increase in thromboembolic events, though causation is unclear. Omalizumab is not a cure; it controls symptoms while on therapy, and once discontinued, symptoms may recur, though some patients experience sustained benefit. Treatment duration is typically at least 6 months, and if effective, it may be continued long-term.

Managing CSU: Practical Tips for Patients

In addition to medical treatment, lifestyle modifications can help reduce exacerbations:

• Avoid known triggers: NSAIDs, alcohol, tight clothing, extreme heat or cold, stress.
• Use fragrance-free, gentle skin care products and cool compresses to soothe itching.
• Keep a symptom diary to identify potential triggers and monitor treatment response.
• Maintain a healthy sleep schedule and manage stress through relaxation techniques or counseling.

Regular follow-up with a dermatologist or allergist is essential to adjust treatment and monitor for adverse effects. For patients on omalizumab, adherence to injection schedules and awareness of anaphylaxis symptoms are important.

Prognosis and Future Directions

The prognosis of CSU is generally favorable, though the course is unpredictable. Up to 50% of patients experience spontaneous resolution within 1–5 years, but some have symptoms for decades. Early effective treatment can improve outcomes and quality of life. Research continues to explore biomarkers predicting response to therapy, new therapeutic targets, and personalized treatment approaches. The introduction of omalizumab for chronic urticaria has been a major advance, and ongoing studies on biologics such as ligelizumab (anti-IgE), benralizumab (anti-IL-5R), and dupilumab (anti-IL-4R) hold promise for further improving outcomes in refractory cases.

In conclusion, chronic spontaneous urticaria is a challenging condition that requires a comprehensive, patient-centered approach. By understanding its symptoms and the role of treatments like omalizumab, patients and healthcare providers can work together to achieve optimal symptom control and improve daily life.